tailieunhanh - báo cáo khoa học: "Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology | Mirshahidi and Hsueh Journal of Hematology Oncology 2010 3 18 http content 3 1 18 JOURNAL OF HEMATOLOGY ONCOLOGY REVIEW Open Access Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology Hamid R Mirshahidi and Chung T Hsueh Abstract We have reviewed the pivotal presentations in non-small cell lung cancer NSCLC from the 2009 annual meeting of the American Society of Clinical Oncology. We have discussed the scientific data the impact on standards of care and ongoing clinical trials. In patients with early-stage NSCLC there is still no data to support the superiority of either neoadjuvant or adjuvant chemotherapy. However adjuvant cisplatin-based chemotherapy has sustained the survival benefits after median follow-up of more than 9 years. The first-line treatment with inhibitors of epidermal growth factor receptor EGFR could be considered for the treatment of EGFR mutated patients with metastatic disease. Several maintenance studies with cytotoxic or biological agents have also demonstrated promising outcomes. Finally novel targeted agents such as inhibitors of histone deacetylase and multi-targeted tyrosine kinase inhibitor have shown promising activity in NSCLC treatment. Introduction The 2009 Annual Meeting of the American Society of Clinical Oncology ASCO in Florida introduced and highlighted numerous important studies and medical advancements. Among them the meeting brought forth much data from several key studies in non-small-cell lung cancer NSCLC . The purpose of this article is to review several important abstracts that were presented in different lung cancer tracts which may influence the standards of care in the future. With that said such abstracts include the Neoadjuvant or Adjuvant Chemotherapy in patients with Operable Non-Small Cell Lung Cancer NATCH trial and the updated long-term follow-up data from adjuvant chemotherapy study in the early stage disease.